

# Tami Livnat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3007685/publications.pdf>

Version: 2024-02-01

160  
papers

2,901  
citations

185998

28  
h-index

223531

46  
g-index

187  
all docs

187  
docs citations

187  
times ranked

2563  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. <i>Lancet Neurology</i> , The, 2007, 6, 595-603.	4.9	184
2	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e18-e27.	2.2	173
3	Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. <i>Blood</i> , 2003, 101, 4783-4788.	0.6	122
4	Plasma Glutathione Peroxidase Deficiency and Platelet Insensitivity to Nitric Oxide in Children With Familial Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2017-2023.	1.1	80
5	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1637-1641.	0.5	75
6	Paediatric cerebral sinus vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2004, 92, 713-718.	1.8	74
7	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. <i>Blood</i> , 2019, 134, 317-320.	0.6	71
8	Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single-center cohort. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27886.	0.8	65
9	Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. <i>Thrombosis and Haemostasis</i> , 2009, 102, 487-492.	1.8	64
10	Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. <i>Haematologica</i> , 2020, 106, 123-129.	1.7	60
11	Emicizumab treatment and monitoring in a paediatric cohort: real-world data. <i>British Journal of Haematology</i> , 2020, 191, 282-290.	1.2	57
12	Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2009, 15, 904-910.	1.0	56
13	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B—the impact of prophylactic treatment. <i>British Journal of Haematology</i> , 2017, 179, 298-307.	1.2	56
14	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein—Jr phase 3 dose—exposure—response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	1.9	52
15	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , the, 2019, 6, e500-e509.	2.2	51
16	Neonatal IVH—the mechanisms and management. <i>Thrombosis Research</i> , 2011, 127, S120-S122.	0.8	50
17	Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 802-809.	1.5	50
18	Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. <i>Thrombosis and Haemostasis</i> , 2016, 116, 659-668.	1.8	50

#	ARTICLE	IF	CITATIONS
19	Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 192-200.	1.9	41
20	Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. <i>Haemophilia</i> , 2008, 14, 782-786.	1.0	41
21	Venous thromboembolism in neonates and children. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 333-344.	0.7	36
22	Developmental hemostasis: A lifespan from neonates and pregnancy to the young and elderly adult in a European white population. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 2-13.	0.6	36
23	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020, 4, 4632-4639.	2.5	35
24	Insights into neonatal thrombosis. <i>Thrombosis Research</i> , 2019, 181, S33-S36.	0.8	34
25	Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring. <i>Haemophilia</i> , 2021, 27, 383-391.	1.0	34
26	The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. <i>Thrombosis Research</i> , 2015, 136, 465-473.	0.8	33
27	Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1242-1255.	1.9	32
28	Hemostasis and Thrombosis in Critically Ill Children. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 451-458.	1.5	31
29	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 1-7.	0.6	30
30	Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. <i>Haematologica</i> , 2019, 104, 2100-2106.	1.7	30
31	Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population. <i>Haematologica</i> , 2019, 104, 1676-1681.	1.7	28
32	Association between hyperflexibility of the thumb and an unexplained bleeding tendency: is it a rule of thumb?. <i>British Journal of Haematology</i> , 1998, 101, 260-263.	1.2	26
33	Thrombophilia does not increase risk for neonatal complications in preterm infants. <i>Thrombosis and Haemostasis</i> , 2003, 90, 823-828.	1.8	25
34	Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. <i>British Journal of Haematology</i> , 2016, 175, 133-140.	1.2	24
35	Thrombosis in pediatric patients with leukemia. <i>Thrombosis Research</i> , 2018, 164, S94-S97.	0.8	24
36	Health-related quality of life in paediatric haemophilia B patients treated with rIXmFP. <i>Haemophilia</i> , 2019, 25, 45-53.	1.0	24

#	ARTICLE	IF	CITATIONS
37	A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. <i>Thrombosis and Haemostasis</i> , 2011, 105, 688-695.	1.8	23
38	Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. <i>Experimental Eye Research</i> , 2016, 146, 224-232.	1.2	23
39	The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 886-892.	1.0	23
40	Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data. <i>Haemophilia</i> , 2021, 27, 253-260.	1.0	23
41	Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents – What did we learn within the last 20 years?. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 18-22.	0.6	22
42	Emicizumab state-of-the-art update. <i>Haemophilia</i> , 2022, 28, 103-110.	1.0	22
43	Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors – a thrombin generation-guided pilot study. <i>Haemophilia</i> , 2013, 19, 782-789.	1.0	21
44	Thrombophilia testing in children: What and when should be tested?. <i>Thrombosis Research</i> , 2018, 164, 75-78.	0.8	21
45	Hemostasis in the Very Young. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 617-623.	1.5	21
46	PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. <i>Haemophilia</i> , 2020, 26, e55-e65.	1.0	20
47	Assessment of Functional Fibrinolysis in Cord Blood Using Modified Thromboelastography. <i>Pediatric Blood and Cancer</i> , 2016, 63, 839-843.	0.8	18
48	In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. <i>Blood Transfusion</i> , 2014, 12, 78-84.	0.3	18
49	Fetal and Neonatal Thrombophilia. <i>Obstetrics and Gynecology Clinics of North America</i> , 2006, 33, 457-466.	0.7	17
50	Inhibitors in Hemophilia: Treatment Challenges and Novel Options. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 544-550.	1.5	17
51	The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients Hospitalized with Acute Pulmonary Embolism. <i>Journal of Clinical Medicine</i> , 2021, 10, 4058.	1.0	17
52	Helicobacter Pylori-Associated Gastric Lymphoma in a Girl. <i>Pediatric Hematology and Oncology</i> , 1997, 14, 177-180.	0.3	16
53	In vitro characterization of MOD5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII. <i>Haemophilia</i> , 2018, 24, 477-486.	1.0	16
54	High adherence to prophylaxis regimens in haemophilia B patients receiving rIXa-FP: Evidence from clinical trials and real-world practice. <i>Haemophilia</i> , 2020, 26, 637-642.	1.0	16

#	ARTICLE	IF	CITATIONS
55	VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina. <i>Current Alzheimer Research</i> , 2015, 12, 323-334.	0.7	16
56	Bleeding issues in neonates and infants – update 2015. <i>Thrombosis Research</i> , 2015, 135, S41-S43.	0.8	15
57	Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. <i>Thrombosis Research</i> , 2016, 148, 145-151.	0.8	15
58	The hemostatic efficacy of chitosan-pads in hemodialysis patients with significant bleeding tendency. <i>Journal of Vascular Access</i> , 2017, 18, 220-224.	0.5	15
59	Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 599-606.	1.8	15
60	Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 4303.	1.0	15
61	Desmoplastic Infantile Ganglioglioma. <i>Acta OncolÃ³gica</i> , 1997, 36, 655-657.	0.8	14
62	Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. <i>Experimental Eye Research</i> , 2016, 145, 412-416.	1.2	14
63	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2022, 161, 524-534.	0.4	14
64	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2274-2282.	1.8	13
65	Inflammation, angiogenesis and coagulation interplay in a variety of retinal diseases. <i>Acta Ophthalmologica</i> , 2020, 98, e559.	0.6	13
66	High-Dose Recombinant Factor VIIa Therapy in Hemophilia Patients With Inhibitors. <i>Seminars in Hematology</i> , 2006, 43, S108-S110.	1.8	12
67	Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). <i>Blood</i> , 2021, 138, LBA-3-LBA-3.	0.6	12
68	Effect of Erythropoietin on Healing of Corneal Epithelial Defects in Rabbits. <i>Ophthalmic Research</i> , 2013, 50, 129-133.	1.0	11
69	Intraventricular haemorrhage in preterm infants – Can we improve outcome by addressing coagulation?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 2265-2267.	0.7	11
70	Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 379-387.	0.5	10
71	Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 62, 24-31.	0.6	10
72	Quantification of specific T and B cells immunological markers in children with chronic and transient ITP. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26646.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Comparison of Subconjunctival Aflibercept and Betamethasone for the Treatment of Formed Corneal Neovascularization in a Rabbit Model. <i>Ophthalmic Research</i> , 2019, 62, 116-122.	1.0	10
74	Long-term safety and efficacy of N8â€œGP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 15-25.	1.9	10
75	Cancer-associated thrombosis in pediatric patients. <i>Thrombosis Research</i> , 2020, 191, S22-S25.	0.8	10
76	Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombinâ€œ-activatable fibrinolysis inhibitor. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 521-529.	0.7	9
77	Primary prophylaxis for children with severe congenital factor VII deficiency â€œ Clinical and laboratory assessment. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 86-90.	0.6	9
78	Rare bleeding disorders-old diseases in the era of novel options for therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 63-68.	0.6	9
79	Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 151-161.	0.5	9
80	The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 714.	1.8	9
81	Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 117-127.	1.8	9
82	Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 82, 102416.	0.6	9
83	The potential role of emicizumab prophylaxis in severe von Willebrand disease. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102530.	0.6	9
84	Prophylaxis in children with haemophilia in an evolving treatment landscape. <i>Haemophilia</i> , 2021, 27, 889-896.	1.0	9
85	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5959.	1.0	9
86	Single-Dose Recombinant Activated Factor VII Therapy in Hemophilia Patients With Inhibitors. <i>Seminars in Hematology</i> , 2008, 45, S38-S41.	1.8	8
87	The effects of the apoE4 genotype on the developing mouse retina. <i>Experimental Eye Research</i> , 2016, 145, 17-25.	1.2	8
88	An extra X does not prevent acquired hemophilia â€œ Pregnancy-associated acquired hemophilia A. <i>Thrombosis Research</i> , 2017, 151, S82-S85.	0.8	8
89	Mobile Laser Indirect Ophthalmoscope: For the Induction of Choroidal Neovascularization in a Mouse Model. <i>Current Eye Research</i> , 2017, 42, 1545-1551.	0.7	8
90	Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 66, 1-5.	0.6	8

#	ARTICLE	IF	CITATIONS
91	From thrombasthenia to next generation thrombocytopenia: Neonatal alloimmune thrombocytopenia induced by maternal Glanzmann thrombasthenia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27376.	0.8	8
92	PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A. <i>Haemophilia</i> , 2021, 27, 434-444.	1.0	8
93	Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9074.	1.8	8
94	Thromboelastography as a Surrogate Marker of Perisurgical Hemostasis in Gaucher Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 693-697.	0.7	7
95	Changes in Retinal Function and Cellular Remodeling Following Experimental Retinal Detachment in a Rabbit Model. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-14.	0.6	7
96	Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1927-1932.	1.8	7
97	Neonatal Sepsis and Hemostasis. <i>Diagnostics</i> , 2022, 12, 261.	1.3	7
98	Bleeding issues in neonates, infants and young children. <i>Thrombosis Research</i> , 2009, 123, S35-S37.	0.8	6
99	Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 480-486.	0.6	6
100	Correlation between Interleukin-6 and Thrombin—Antithrombin III Complex Levels in Retinal Diseases. <i>Current Eye Research</i> , 2017, 42, 1269-1272.	0.7	6
101	Treatment tailoring for factor V deficient patients and perioperative management using global hemostatic coagulation assays. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 71, 5-10.	0.6	6
102	Heparin-induced thrombocytopenia complicating children after the Fontan procedure: Single-center experience and review of the literature. <i>Congenital Heart Disease</i> , 2018, 13, 16-25.	0.0	6
103	Activated protein C induces suppression and regression of choroidal neovascularization—A murine model. <i>Experimental Eye Research</i> , 2019, 186, 107695.	1.2	6
104	Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 494-501.	1.0	6
105	Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction. <i>Biomolecules</i> , 2021, 11, 358.	1.8	5
106	Transcleral approach for closing retinal tears using DuraSeal, a hydrogel sealant. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 238.	0.5	5
107	Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 208-216.	0.3	5
108	Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG—correlation with thrombin generation and thromboelastometry. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 673-679.	0.5	4

#	ARTICLE	IF	CITATIONS
109	Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A - an Israeli-German multicenter database study. <i>Thrombosis Research</i> , 2014, 133, 544-549.	0.8	4
110	Skin Necrosis and Purpura Fulminans in Children With and Without Thrombophilia – A Tertiary Center's Experience. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 505-510.	0.3	4
111	Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27381.	0.8	4
112	Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-ES can continue their dosing schedule with improved protection. <i>Haemophilia</i> , 2020, 26, e145-e147.	1.0	4
113	Mutations in RASGRP2 gene identified in patients misdiagnosed as Glanzmann thrombasthenia patients. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 89, 102560.	0.6	4
114	Thrombin Generation Test Can Predict Bleeding Tendency In Patients With Severe Factor XI Deficiency. <i>Blood</i> , 2013, 122, 3600-3600.	0.6	4
115	Hemostasis and Thrombosis in Pediatric Patients: Special Issues and Unique Concerns. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 721-722.	1.5	3
116	Quantitation of bleeding symptoms in a national registry of patients with inherited platelet disorders. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 59-62.	0.6	3
117	A Proposed Role of Surfactant in Platelet Function and Treatment of Pulmonary Hemorrhage in Preterm and Term Infants. <i>Acta Haematologica</i> , 2018, 140, 215-220.	0.7	3
118	A novel approach using ancillary tests to guide treatment of Glanzmann thrombasthenia patients undergoing surgical procedures. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 44-48.	0.6	3
119	Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature. <i>TH Open</i> , 2021, 05, e183-e187.	0.7	3
120	European Collaborative Paediatric Database on Cerebral Sinus Venous Thrombosis (CVT): Risk of Recurrent Venous Thrombosis (Update 2005).. <i>Blood</i> , 2005, 106, 1629-1629.	0.6	3
121	Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results. <i>Blood</i> , 2020, 136, 36-37.	0.6	3
122	Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 95, 102663.	0.6	3
123	Dehydration as a Rare Cause of Pulmonary Artery Thrombosis in a 2-Week-Old Term Neonate. <i>Journal of Pediatric Intensive Care</i> , 2018, 07, 102-105.	0.4	2
124	Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 80, 102370.	0.6	2
125	Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. <i>Thrombosis Research</i> , 2020, 189, 96-101.	0.8	2
126	Essential thrombocythemia A retrospective case series. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28183.	0.8	2



#	ARTICLE	IF	CITATIONS
127	Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course. <i>Pediatric Research</i> , 2021, 90, 93-98.	1.1	2
128	Catheter-directed thrombolysis for in situ pulmonary artery thrombosis in children. <i>Annals of Pediatric Cardiology</i> , 2021, 14, 211.	0.2	2
129	BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
130	Pediatric severe factor XI deficiency: A multicenter study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29545.	0.8	2
131	Spinal Epidural Hematoma Following Cupping Glass Treatment in an Infant With Hemophilia A. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1120-1122.	0.8	1
132	A man-made disease: Fetal neonatal alloimmune thrombocytopenia due to incompatibility between oocyte donor and gestational mother. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26447.	0.8	1
133	Severe Protein C Deficiency due to Novel Biallelic Variants in <i>PROC</i> and Their Phenotype Correlation. <i>Acta Haematologica</i> , 2021, 144, 327-331.	0.7	1
134	Dabigatran etexilate and treatment of acute venous thromboembolism in children. <i>Lancet Haematology</i> , 2021, 8, e2-e3.	2.2	1
135	Novel mutation in coagulation factor VII (Carmel mutation): Identification and characterization. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12407.	1.0	1
136	Post-Thrombotic Syndrome (PTS) in Children: A Systematic Review of Prevalence, Validity of Outcome Measures, and Prognostic Factors.. <i>Blood</i> , 2009, 114, 2978-2978.	0.6	1
137	European Collaborative Paediatric Database on Cerebral Venous Thrombosis: Risk Factors for Recurrent Venous Thromboembolism.. <i>Blood</i> , 2006, 108, 276-276.	0.6	1
138	Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 94, 102651.	0.6	1
139	Author's reply to: Al-Abdi SY. Virus-inactivated plasma and intraventricular hemorrhage in preterm neonates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 1289-1289.	0.7	0
140	Cerebral sinovenous thrombosis in children and neonates. , 0, , 33-46.		0
141	Pediatric thrombophilia evaluation: Considerations for primary and secondary venous thromboembolism prevention. , 0, , 133-141.		0
142	A Genetic Origin? Purpura Fulminans. <i>American Journal of Medicine</i> , 2019, 132, 327-328.	0.6	0
143	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. <i>Thrombosis and Haemostasis</i> , 2021, , .	1.8	0
144	Platelet Adrenergic Receptor Dysfunction Is Associated with Both Aggregation and Adhesion Defects: Application of the Cone and Plate(let) Analyzer for Diagnosis and Monitoring of the Response to DDAVP Therapy.. <i>Blood</i> , 2004, 104, 3039-3039.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Validation of a Predictive Model for Identifying An Increased Risk for Thromboembolism in Children with Acute Lymphoblastic Leukemia: Results of a Multicenter Cohort Study. <i>Blood</i> , 2008, 112, 524-524.	0.6	0
146	Risk Factors for Central Venous Line-Related Deep Vein Thrombosis and Occlusions in the Israeli Pediatric Oncology Registry.. <i>Blood</i> , 2008, 112, 1814-1814.	0.6	0
147	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. <i>Blood</i> , 2009, 114, 3993-3993.	0.6	0
148	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. <i>Blood</i> , 2009, 114, 3154-3154.	0.6	0
149	Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.. <i>Blood</i> , 2009, 114, 4443-4443.	0.6	0
150	Impact of SERPINC1, PROC and PROS1 Mutations on the Thrombotic Phenotype in Children with Venous Thromboembolism: An Observational Multicenter Cohort Study. <i>Blood</i> , 2014, 124, 583-583.	0.6	0
151	Efficacy and Safety of Rivaroxaban: An Observational multicenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT. <i>Blood</i> , 2014, 124, 5083-5083.	0.6	0
152	Influence of Gender and Coagulation Factors on Efficacy and Safety of Rivaroxaban in Adolescents & Young Adults with Venous Thromboembolism. <i>Blood</i> , 2015, 126, 4729-4729.	0.6	0
153	Neonatal circumcision in patients with haemophilia is safe – a single centre experience. <i>The Journal of Haemophilia Practice</i> , 2017, 4, 32-34.	0.2	0
154	99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry. <i>Blood</i> , 2018, 132, 2472-2472.	0.6	0
155	Recurrent Stroke: The Role of Thrombophilia in a Large International Pediatric Stroke Population. <i>Blood</i> , 2018, 132, 3808-3808.	0.6	0
156	A Single Low-Dose of Methylphenidate Improves Abnormal Visual Field Testing. <i>Current Eye Research</i> , 2021, 46, 1232-1239.	0.7	0
157	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENE8-1 Phase 3 Trial. <i>Blood</i> , 2021, 138, 3972-3972.	0.6	0
158	Genotype-Phenotype Relationship Among 1200 Unrelated White Patients with Inherited FVII Deficiency: A Three-Center Database Study. <i>Blood</i> , 2021, 138, 589-589.	0.6	0
159	Improvement of Efficacy Outcomes in Patients Who Switched from Sucrose-Formulated rFVIII to BAY 81-8973 Prophylaxis in the LEOPOLD Clinical Trials. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
160	Evaluation of pro-angiogenic and pro-coagulant activity of irradiated and non irradiated stored blood used in transfusion practice. <i>Journal of Clinical Oncology</i> , 2004, 22, 9710-9710.	0.8	0